Allyson Ocean, MD, discusses the need for additional second-line therapies in metastatic pancreatic cancer.
Allyson Ocean, MD, an associate attending physician, NewYork-Presbyterian Hospital, and associate professor of clinical medicine at Weill Cornell Medicine, discusses the need for additional second-line therapies in metastatic pancreatic cancer.
FOLFIRINOX and the combination of gemcitabine plus nab-paclitaxel (Abraxane) have demonstrated survival advantages in the first-line setting for patients with metastatic pancreatic cancer, says Ocean. However, these patients often progress and require second-line therapy.
Notably, the unmet need in this space led to the development of nanoliposomal irinotecan (Onivyde), a unique compound that can induce a prolonged response and better cell kill, Ocean concludes.